.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,676,929

« Back to Dashboard

Details for Patent: 5,676,929

Title: Canister containing aerosol formulations containing P134a and particulate medicaments
Abstract:This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Inventor(s): Akehurst; Rachel Ann (Ware, GB3), Taylor; Anthony James (Ware, GB3), Wyatt; David Andrew (Ware, GB3)
Assignee: Glaxo Group Limited (London, GB2)
Filing Date:May 19, 1995
Application Number:08/444,743
Claims:1. A canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt and that when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.

2. A canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting of particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is in the form of a physiologically acceptable salt and that when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.

3. A canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is a plastics-coated aluminum can and is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is salbutamol sulphate and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of salbutamol sulphate, the particulate medicament being present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and with the provisos than when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt and that when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.

4. A canister as claimed in claim 1 wherein the container is plastics-coated, lacquer coated or anodized.

5. A canister as claimed in claim 1 wherein the container is a metal can.

6. A canister as claimed in claim 1 wherein the container is a metal can, which is plastics-coated.

7. A canister as claimed in claim 1 wherein the container is an aluminum can.

8. A canister as claimed in claim 1 wherein the container is an aluminum can which is plastics-coated.

9. A canister as claimed in claim 1 wherein the formulation is free of surfactant.

10. A canister as claimed in claim 1 wherein the salbutamol is in the form of its sulphate salt.

11. A metered dose inhaler which comprises a canister as claimed in claim 1 fitted into a channelling device for nasal or oral inhalation of the pharmaceutical aerosol formulation.

12. A canister as claimed in claim 1 wherein the medicament is present in an amount of 0.01% to 1% w/w based upon the total weight of the formulation.

13. A canister as claimed in claim 1 wherein the formulation has a respirable fraction of 20% or more by weight of the medicament.

14. A canister as claimed in claim 2 wherein the container is plastics-coated, lacquer coated or anodized.

15. A canister as claimed in claim 2 wherein the container is a metal can.

16. A canister as claimed in claim 2 wherein the container is a metal can, which is plastics-coated.

17. A canister as claimed in claim 2 wherein the container is an aluminum can.

18. A canister as claimed in claim 2 wherein the container is an aluminum can which is plastics-coated.

19. A canister as claimed in claim 2 wherein the salbutamol or physiologically acceptable salt or solvate thereof is present in an amount of 0.01 to 1% w/w based upon the total weight of the formulation.

20. A canister as claimed in claim 2 wherein the formulation has a respirable fraction of 20% or more by weight of salbutamol or physiologically acceptable salt or solvate thereof.

21. A metered dose inhaler which comprises a canister as claimed in claim 2 fitted into a channelling device for nasal or oral inhalation of the pharmaceutical aerosol formulation.

22. A canister as claimed in claim 1 wherein the pharmaceutical aerosol formulation is in a form for inhalation into lungs of a patient.

23. A canister as claimed in claim 2 wherein the salbutamol is in the form of its sulphate salt.

24. A canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting essentially of particulate medicaments which are salbutamol and beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of particulate medicaments, the particulate medicaments being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

25. A canister suitable for delivering a pharmaceutical aerosol formulation for inhalation therapy which comprises a container capable of withstanding the vapor pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation consisting of particulate medicaments which are salbutamol and beclomethasone dipropionate and physiologically acceptable salts and solvates thereof, and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.

26. A canister as claimed in claim 24 in which the formulation is free of surfactant.

27. A canister as claimed in claim 24 in which the salbutamol is in the form of its sulphate salt.

28. A canister as claimed in claim 24 wherein the particulate medicaments are present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation.

29. A canister as claimed in claim 25 in which the salbutamol is in the form of its sulphate salt.

30. A canister as claimed in claim 25 wherein the particulate medicaments are present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc